Alessio Giubellino

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e56083. 2013
  2. ncbi Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892 1109, USA
    Cancer Lett 316:46-52. 2012
  3. ncbi Grb2 signaling in cell motility and cancer
    Alessio Giubellino
    National Cancer Institute, Urologic Oncology Branch, CCR, Building 10, 10 Center Drive MSC 1107, Bethesda, MD 20892 1107, USA
    Expert Opin Ther Targets 12:1021-33. 2008
  4. ncbi Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist
    Alessio Giubellino
    Urologic Oncology Branch, Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1107, USA
    Cancer Res 67:6012-6. 2007
  5. ncbi Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist
    Alessio Giubellino
    Urologic Oncology Branch and Laboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Med Chem 51:7459-68. 2008
  6. ncbi Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Endocrinology 154:646-55. 2013
  7. ncbi Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma
    Carole Sourbier
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cell Cycle 9:4183-9. 2010
  8. ncbi Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids
    Won Jun Choi
    Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute, National Insitutes of Health, Frederick, Maryland 21702, USA
    J Med Chem 52:1612-8. 2009
  9. ncbi Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides
    Fa Liu
    Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI Frederick, Frederick, MD 21702, USA
    Biopolymers 96:780-8. 2011
  10. ncbi NF-κB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model
    Karel Pacak
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 131:2445-55. 2012

Collaborators

Detail Information

Publications16

  1. ncbi Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e56083. 2013
    ..Levels of Hsp70 in plasma from the xenograft studies served as a proximal biomarker of drug treatment. Our study suggests that targeting Hsp90 may benefit patients with advanced pheochromocytoma...
  2. ncbi Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD 20892 1109, USA
    Cancer Lett 316:46-52. 2012
    ....
  3. ncbi Grb2 signaling in cell motility and cancer
    Alessio Giubellino
    National Cancer Institute, Urologic Oncology Branch, CCR, Building 10, 10 Center Drive MSC 1107, Bethesda, MD 20892 1107, USA
    Expert Opin Ther Targets 12:1021-33. 2008
    ..Metastasis is the primary cause of death in most human cancers, and understanding the molecular mechanisms underpinning this multistep process is fundamental to identifying novel molecular targets and developing more effective therapies...
  4. ncbi Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist
    Alessio Giubellino
    Urologic Oncology Branch, Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1107, USA
    Cancer Res 67:6012-6. 2007
    ..These results support the potential efficacy of this compound in reducing the metastatic spread of primary solid tumors and establish a critical role for Grb2 Src homology-2 domain-mediated interactions in this process...
  5. ncbi Selectivity and mechanism of action of a growth factor receptor-bound protein 2 SRC homology 2 domain binding antagonist
    Alessio Giubellino
    Urologic Oncology Branch and Laboratory of Cell Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Med Chem 51:7459-68. 2008
    ..This approach to defining protein binding antagonist selectivity and molecular basis of action should be widely applicable in drug development...
  6. ncbi Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice
    Alessio Giubellino
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Endocrinology 154:646-55. 2013
    ..This study suggests that targeting both mTORC1 and mTORC2 is a potentially rewarding strategy and supports the application of selective inhibitors in combinatorial drug regimens for metastatic pheochromocytoma...
  7. ncbi Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma
    Carole Sourbier
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cell Cycle 9:4183-9. 2010
    ..Increasing tumor ROS with bortezomib in combination with cisplatin represents a novel targeted therapeutic approach to treat advanced HLRCC-associated renal tumors...
  8. ncbi Identification of Shc Src homology 2 domain-binding peptoid-peptide hybrids
    Won Jun Choi
    Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute, National Insitutes of Health, Frederick, Maryland 21702, USA
    J Med Chem 52:1612-8. 2009
    ..These results could provide a foundation for further structural optimization of Shc SH2 domain-binding peptide mimetics...
  9. ncbi Application of ring-closing metathesis to Grb2 SH3 domain-binding peptides
    Fa Liu
    Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI Frederick, Frederick, MD 21702, USA
    Biopolymers 96:780-8. 2011
    ..The synthetic approach may be useful in RCM macrocyclizations, where maintenance of proline integrity at both ring junctures is desired...
  10. ncbi NF-κB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model
    Karel Pacak
    Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Int J Cancer 131:2445-55. 2012
    ....
  11. ncbi Targeting the Met signaling pathway in renal cancer
    Alessio Giubellino
    Urologic Oncology Branch, CCR, National Cancer Institute, Bethesda, MD 20892 21107, USA
    Expert Rev Anticancer Ther 9:785-93. 2009
    ..This review will focus on efforts to understand the role of the Met signaling pathway in renal cancer and how this has contributed to the development of potent and selective drug candidates...
  12. ncbi Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis
    Fa Liu
    Laboratory of Medicinal Chemistry, Bldg 376 Boyles St, Center for Cancer Research, NCI Frederick, National Institutes of Health, Frederick, MD 21702, USA
    Org Biomol Chem 5:367-72. 2007
    ..9 nM). The results of this study advance design considerations that should facilitate the development of Grb2 SH2 domain-binding antagonists...
  13. ncbi Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy
    Pathirage G Dharmawardana
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1107, USA
    Anticancer Drugs 17:13-20. 2006
    ..These novel compounds offer considerable promise in our growing arsenal of rationally designed anti-cancer therapeutics...
  14. ncbi c-Met ectodomain shedding rate correlates with malignant potential
    Gagani Athauda
    Urologic Oncology Branch, Laboratory of Molecular Pharmacology, and Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1107, USA
    Clin Cancer Res 12:4154-62. 2006
    ..We hypothesized that c-Met overexpression in cancer might result in increased ectodomain shedding, and that its measure could be a useful biomarker of tumor progression...
  15. ncbi Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells
    Angelina Felici
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National, Institutes of Health, Bethesda, Maryland 20892 1501, USA
    J Cell Biochem 111:310-21. 2010
    ..Our results suggest that in myeloid cells, Gab1 is likely to enhance HGF mitogenicity by coupling Met to Shp-2 and GATA-2 expression, thereby potentially contributing to normal myeloid differentiation as well as oncogenic transformation...
  16. ncbi Microarray analysis sheds light on the dedifferentiating role of agouti signal protein in murine melanocytes via the Mc1r
    Elodie Le Pape
    Pigment Cell Biology Section, Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:1802-7. 2009
    ....